Pharmaceuticals company Camlin Fine Sciences announced Q1FY25 results: Revenue stood at Rs 395.85 crore which is slightly lower by 1.5% as compared to last quarter The gross margins are at 44.9% as compared to 34.9% in last quarter. Margins are facing pricing headwinds, sluggish global demand and increasing raw material prices Sustained dominance in Blends business with a growth of 13.4% quarter on quarter which is expected to continue EBITDA margins improved by 606 bps but will remain under pressure Profitability was further impacted by foreign exchange volatility in South American subsidiaries Vanillin Plant commenced campaign for Vanillin at the end of May 2024 and we expect ramp of sales from the later part of Q2FY25 Inorganic growth in Blends expected in future with successful acquisition of Vitafor Invest NV Belgium with its product portfolio and presence in North African & East European markets Result PDF
Conference Call with Camlin Fine Sciences Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.